A theme centered on entering the regenerative medicine and cell development businesses and turning them profitable by combining funding and aesthetic medicine management expertise through an investment in ルミライズ and a policy of making it a subsidiary. ルミライズ later became an equity-method affiliate in which the company held 35.99% of the voting rights, and the company has also provided loans.